Growth Metrics

Xeris Biopharma Holdings (XERS) Non Operating Income (2020 - 2025)

Historic Non Operating Income for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to -$6.1 million.

  • Xeris Biopharma Holdings' Non Operating Income rose 95.64% to -$6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.4 million, marking a year-over-year decrease of 2440.47%. This contributed to the annual value of -$23.5 million for FY2024, which is 2033.45% down from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Non Operating Income of -$6.1 million as of Q3 2025, which was up 95.64% from -$6.4 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Non Operating Income registered a high of $1.9 million during Q4 2022, and its lowest value of -$7.6 million during Q3 2023.
  • Its 5-year average for Non Operating Income is -$4.4 million, with a median of -$4.5 million in 2023.
  • Data for Xeris Biopharma Holdings' Non Operating Income shows a peak YoY increase of 17550.62% (in 2022) and a maximum YoY decrease of 34027.78% (in 2022) over the last 5 years.
  • Xeris Biopharma Holdings' Non Operating Income (Quarter) stood at -$2.5 million in 2021, then soared by 175.51% to $1.9 million in 2022, then tumbled by 299.0% to -$3.8 million in 2023, then crashed by 79.45% to -$6.8 million in 2024, then rose by 10.04% to -$6.1 million in 2025.
  • Its Non Operating Income was -$6.1 million in Q3 2025, compared to -$6.4 million in Q2 2025 and -$6.1 million in Q1 2025.